All In Biotech

Free tool

FAERS Monitor: Lemtrada

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103948 or its brand name (Lemtrada, Alemtuzumab). Reports on generic versions are filed under their own applications.

Reports

19,365

Serious

16,665

86% of reports

Hospitalization

6,156

Death reported

2,947

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache1,906
  • fatigue1,874
  • pyrexia1,784
  • off label use1,698
  • rash1,200
  • nausea1,190
  • drug ineffective1,032
  • dyspnoea985
  • asthenia942
  • multiple sclerosis relapse923
  • lymphocyte count decreased879
  • cytomegalovirus infection839
  • urinary tract infection835
  • pain755
  • condition aggravated725

Reports by year received

View as table
YearReports
2004153
2005150
2006150
2007189
2008336
2009373
2010363
2011704
2012320
2013427
2014486
2015985
20161,627
20171,750
20182,274
20192,380
20201,690
20211,288
20221,072
2023849
2024738
2025635
2026425

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,794 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytomegalovirus infectionSignal83957.753.944,361
lymphocyte count decreasedSignal87956.853.145,767
multiple sclerosis relapseSignal92314.813.911,753
pyrexiaSignal1,7845.65.46,855
urinary tract infectionSignal8355.35.02,949
headacheSignal1,9063.33.23,153
rashSignal1,2003.02.81,622
astheniaSignal9422.72.61,043
fatigueSignal1,8742.62.51,940
condition aggravatedSignal7252.62.4717
off label useSignal1,6982.12.01,029
dyspnoea9851.91.8424
nausea1,1901.61.5303
pain7551.31.265
drug ineffective1,0320.90.829

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.